



ABN 53 075 582 740

2 September 2021

---

## Section 708A Notice

This notice is given by Bionomics Limited (**Company**) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

The Company hereby confirms that it has today:

- (a) issued 2,000,000 fully paid ordinary shares at an issue price of \$0.0136 as a result of the exercise of 2,000,000 unlisted options issued under the Company's Employee Equity Plan;
- (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) Section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Released on authority of the Board

### FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin  
Company Secretary  
[CoSec@bionomics.com.au](mailto:CoSec@bionomics.com.au)

### About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF) is a clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best-in-class, novel drug candidates for patients affected by central nervous system (CNS) disorders. Bionomics' lead drug candidate BNC210 is a negative allosteric modulator of the  $\alpha 7$  nicotinic acetylcholine receptor. BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-



Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA. BNC210 is also being evaluated as an acute treatment in Social Anxiety Disorder (SAD) patients and is expected to enter a Phase 2 trial. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences, to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4- Methylenedioxymethamphetamine (MDMA) derivative EMP-01 for the treatment of PTSD. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.